RVL Pharmaceuticals PLC
OTC:RVLPQ

Watchlist Manager
RVL Pharmaceuticals PLC Logo
RVL Pharmaceuticals PLC
OTC:RVLPQ
Watchlist
Price: 0.0001 USD
Market Cap: 111 USD

RVL Pharmaceuticals PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

RVL Pharmaceuticals PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
RVL Pharmaceuticals PLC
OTC:RVLPQ
Operating Income
-$42.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.9B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$16.1B
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
19%
Pfizer Inc
NYSE:PFE
Operating Income
$18.3B
CAGR 3-Years
-23%
CAGR 5-Years
12%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Operating Income
$24.5B
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Operating Income
$26.4B
CAGR 3-Years
46%
CAGR 5-Years
34%
CAGR 10-Years
22%
No Stocks Found

RVL Pharmaceuticals PLC
Glance View

Market Cap
111 USD
Industry
Pharmaceuticals

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 156 full-time employees. The company went IPO on 2018-10-12. The firm is focused on developing and commercializing eyecare and medical aesthetics products. The firm is engaged in the development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The firm delivers Upneeq (oxymetazoline hydrocholoride ophthalmic solution, 0.1%) for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is the non-surgical treatment option for acquired blepharoptosis.

RVLPQ Intrinsic Value
Not Available

See Also

What is RVL Pharmaceuticals PLC's Operating Income?
Operating Income
-42.8m USD

Based on the financial report for Dec 31, 2022, RVL Pharmaceuticals PLC's Operating Income amounts to -42.8m USD.

What is RVL Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 1Y
47%

Over the last year, the Operating Income growth was 47%.

Back to Top